31 March 2023 in Consortium Psychiatricum
МГМалюкова Наталья Георгиевна
Малюкова Наталья Георгиевна
+6
BACKGROUND: Patients in general hospitals often display concomitant signs of mental maladjustment: low mood, anxiety, apathy, asthenia, all of which can have a negative impact on the course of the underlying disease and the recovery process. One of the non-pharmacological approaches that has gained wider acceptance in medical practice in recent years is the use of procedures based on virtual reality. AIM: Assess the efficacy of the new domestic, virtual reality application Flow as relates to symptoms of anxiety and asthenia in patients undergoing inpatient treatment. METHODS: The study was open-label and had a comparison group; the patients were assigned to the experimental or control group using a randomization table. The patients were assessed using the Spielberger State Anxiety Inventory; the Fatigue Symptom Rating Scale; the Well-being, Activity, Mood questionnaire; the Depression Anxiety Stress Scale; and the Clinical Global Impression Scale. Physical parameters were measured before and after each virtual reality session. The obtained data were statistically processed. RESULTS: The study involved 60 patients. In 40 patients, the treatment program included a course of five daily relaxation sessions in virtual reality; the control group consisted of 20 patients, who were treated in accordance with the usual practice of the institution. The addition of virtual reality sessions to the standard treatment course yielded significant advantage in terms of affective symptoms reduction in patients both after a single session and as a result of undergoing the full course, and several days after its completion. The patients in the experimental group also showed a significant decrease in blood pressure after the sessions, and this was most pronounced in individuals who initially had elevated and high blood pressure. CONCLUSION: The use of relaxation program courses in the virtual reality application Flow is an effective and promising means of non-pharmacological care for non-psychiatric inpatients showing symptoms of anxiety, apathy, depressive mood, as well as hypertension.
20 August 2024 in Neurology, Neuropsychiatry, Psychosomatics
Post-traumatic cognitive impairment (CI) and asthenia are common, disabling and often obligatory manifestations of traumatic brain injury (TBI). The search for effective drugs against CI and asthenia after TBI is of great importance. Objective: to investigate the efficacy and safety of Prospekta in the treatment of post-traumatic CI and asthenia in real-life clinical practice. Material and methods. The observational study involved 50 patients of both sexes aged 21–45 years (mean age 41.5 ± 5.9 years) with complaints of CI and fatigue after TBI received within the last 2 years, who were prescribed 1 tablet of Prospekta twice daily for 4 weeks. Cognitive functions, particularly the speed of attention switching, were assessed using the Schulte table method, visual-motor abilities were assessed using the Trail Making Test (TMT). Asthenic syndrome was assessed using the subjective asthenia rating scale (Multidimensional Fatigue Inventory, MFI-20). At the end of treatment, the safety of therapy and TBI outcomes were assessed using Dobrokhotova's differentiated TBI outcomes scale. Results. The average time to complete the Schulte table technique after 4 weeks of therapy with Prospekta decreased by 16.2 seconds, part A of the TMT – by 6.6 seconds and part B – by 19.8 seconds (p < 0.0001). The average score on the MFI-20 scale decreased by an average of 8 points after 4 weeks of therapy (p < 0.0001), which was mainly due to an increase in motivation (by 22 %), activity (by 16 %) and a decrease in emotional lability (by 20 %). The average score on Dobrokhotova's differentiated TBI outcome scale at the end of therapy was 3.2 ± 1.2 (mild/moderate asthenia). Treatment with Prospekta halved the number of patients with clinically significant mental asthenia, reduced motivation and reduced activity after TBI. No adverse events were recorded. Conclusion. The drug Prospekta can be recommended for monotherapy in patients with TBI to improve cognitive function and reduce asthenic syndrome in real-life clinical practice, contributing to the improvement of quality of life and functional activity of the injured individuals.